Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Lilly pays $50 million upfront to use Entos Pharmaceuticals’ Fusogenix nucleic acid delivery technology

By Brian Buntz | January 6, 2022

Entos/Lilly
Eli Lilly (NYSE:LLY) has acquired exclusive rights to Entos Pharmaceuticals’ Fusogenix proteolipid vehicle (PLV) drug-delivery technology for central and peripheral nervous system applications.

Indianapolis-based Lilly plans on using the platform to discover and develop nucleic acid products.

Entos said Fusogenix brings together the best features of viral and lipid-based delivery approaches while avoiding their respective downsides.

Lilly is optimistic that Fusogenix could help it address hurdles tied to nucleic acid therapeutic modalities.

In the collaboration, Edmonton, Canada–based Entos will focus on creating and optimizing PLVs, while Lilly will select PLVs it intends to use for clinical development and commercialization.

Fusogenix

The Fusogenix platform delivers a proteo-lipid vehicle (PLV) payloadinto the cytoplasm. Fusogenix image courtesy of Entos Pharmaceuticals

Lilly will pay Entos $50 million upfront and could pay up to $400 million in additional milestone payments per program. Entos also could receive royalties from commercialized products stemming from the collaboration.

“Nucleic acid-based therapies hold great promise in addressing the biologic cause of many serious diseases that have significant unmet medical need,” said Andrew Adams, vice president, Lilly Genetic Medicine, in a statement. “Overcoming barriers to the safe and effective delivery of such therapies to specific target cells is essential to realizing their potential.”

Separately, Entos has tested its Fusogenix platform in a DNA-based COVID-19 vaccine. Known as Covigenix VAX-001, the investigational vaccine is now the subject of a Phase 2 study.

 


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development
Tagged With: Eli Lilly, Entos Pharmaceuticals, Fusogenix, nucleic acid therapeutic modalities, PLV, proteolipid vehicle
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Janssen
Janssen’s company group chairman dishes on growth strategy
Curebase
Curebase raises $40 million in Series B funding round 

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50